Vertex Pharma (VRTX) Tops Q2 EPS by 3c, raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $466.79 +3.36%
EPS Growth %: +4.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +4.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.42 billion.
Guidance:
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- AeroVironment restates quarterly financials, citing $89M goodwill error
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
